{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:32Z","timestamp":1792569332859,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10120-021-01218-0","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T05:04:27Z","timestamp":1628658267000},"page":"180-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601"],"prefix":"10.1007","volume":"25","author":[{"given":"Masaaki","family":"Iwatsuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Orita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigekazu","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Arigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-9366","authenticated-orcid":false,"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Tobimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"1218_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1218_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10120-017-0716-7","volume":"21","author":"H Katai","year":"2018","unstructured":"Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001\u20132007). Gastric Cancer. 2018;21:144\u201354.","journal-title":"Gastric Cancer"},{"key":"1218_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000494406","volume":"99","author":"Y Imamura","year":"2019","unstructured":"Imamura Y, Watanabe M, Toihata T, et al. Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma and microsatellite instability status in japanese patients. Digestion. 2019;99:6\u201313.","journal-title":"Digestion"},{"key":"1218_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-020-00785-y","volume":"18","author":"M Watanabe","year":"2021","unstructured":"Watanabe M, Tachimori Y, Oyama T, et al. Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus. 2021;18:1\u201324.","journal-title":"Esophagus"},{"key":"1218_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/1940-6207.CAPR-08-0170","volume":"1","author":"MJ Blaser","year":"2008","unstructured":"Blaser MJ. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev Res (Phila). 2008;1:308\u201311.","journal-title":"Cancer Prev Res (Phila)"},{"key":"1218_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10120-016-0663-8","volume":"20","author":"H Yamashita","year":"2017","unstructured":"Yamashita H, Seto Y, Sano T, et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017;20:69\u201383.","journal-title":"Gastric Cancer"},{"key":"1218_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"1218_CR8","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","volume":"28","author":"C Schuhmacher","year":"2010","unstructured":"Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210\u20138.","journal-title":"J Clin Oncol"},{"key":"1218_CR9","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715\u201321.","journal-title":"J Clin Oncol"},{"key":"1218_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","volume":"27","author":"M Stahl","year":"2009","unstructured":"Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851\u20136.","journal-title":"J Clin Oncol"},{"key":"1218_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"1218_CR12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s10120-019-00941-z","volume":"22","author":"M Terashima","year":"2019","unstructured":"Terashima M, Iwasaki Y, Mizusawa J, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer. 2019;22:1044\u201352.","journal-title":"Gastric Cancer"},{"key":"1218_CR13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10120-015-0549-1","volume":"19","author":"H Bando","year":"2016","unstructured":"Bando H, Yamada Y, Tanabe S, et al. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer. 2016;19:919\u201326.","journal-title":"Gastric Cancer"},{"key":"1218_CR14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s00595-015-1276-2","volume":"46","author":"Y Honma","year":"2016","unstructured":"Honma Y, Yamada Y, Terazawa T, et al. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Surg Today. 2016;46:1076\u201382.","journal-title":"Surg Today"},{"key":"1218_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/jso.24917","volume":"117","author":"X Liu","year":"2018","unstructured":"Liu X, Li G, Long Z, et al. Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer. J Surg Oncol. 2018;117:692\u20138.","journal-title":"J Surg Oncol"},{"key":"1218_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1186\/s12885-018-4480-9","volume":"18","author":"G Wang","year":"2018","unstructured":"Wang G, Zhao J, Song Y, et al. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer. BMC Cancer. 2018;18:547.","journal-title":"BMC Cancer"},{"key":"1218_CR17","doi-asserted-by":"publisher","first-page":"e000130","DOI":"10.1136\/esmoopen-2016-000130","volume":"2","author":"H Satake","year":"2017","unstructured":"Satake H, Miki A, Kondo M, et al. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI). ESMO Open. 2017;2:e000130.","journal-title":"ESMO Open"},{"key":"1218_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"Japanese Gastric Cancer A","year":"2011","unstructured":"Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101\u201312.","journal-title":"Gastric Cancer"},{"issue":"1\u201319","key":"1218_CR19","first-page":"2017","volume":"20","author":"Japanese Gastric Cancer A","year":"2017","unstructured":"Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines, 2014 (ver. 4). Gastric Cancer. 2017;20(1\u201319):2017.","journal-title":"Gastric Cancer"},{"key":"1218_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg"},{"key":"1218_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jso.24096","volume":"113","author":"H Okabe","year":"2016","unstructured":"Okabe H, Hata H, Ueda S, et al. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03. J Surg Oncol. 2016;113:36\u201341.","journal-title":"J Surg Oncol"},{"key":"1218_CR22","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1245\/s10434-014-3594-9","volume":"21","author":"E Oki","year":"2014","unstructured":"Oki E, Emi Y, Kusumoto T, et al. Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer. Ann Surg Oncol. 2014;21:2340\u20136.","journal-title":"Ann Surg Oncol"},{"key":"1218_CR23","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00280-013-2130-0","volume":"71","author":"A Tsuburaya","year":"2013","unstructured":"Tsuburaya A, Nagata N, Cho H, et al. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol. 2013;71:1309\u201314.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1218_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S1470-2045(06)70766-5","volume":"7","author":"M Sasako","year":"2006","unstructured":"Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7:644\u201351.","journal-title":"Lancet Oncol"},{"key":"1218_CR25","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","journal-title":"Lancet"},{"key":"1218_CR26","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s10120-018-0884-0","volume":"22","author":"K Hosoda","year":"2019","unstructured":"Hosoda K, Azuma M, Katada C, et al. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. Gastric Cancer. 2019;22:598\u2013606.","journal-title":"Gastric Cancer"},{"key":"1218_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1634\/theoncologist.2019-0601","volume":"25","author":"T Terazawa","year":"2020","unstructured":"Terazawa T, Matsuyama J, Goto M, et al. A phase II study of perioperative capecitabine plus oxaliplatin therapy for clinical SS\/SE N1\u20133 M0 gastric cancer (OGSG 1601). Oncologist. 2020;25:119-e208.","journal-title":"Oncologist"},{"key":"1218_CR28","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1245\/s10434-014-3664-z","volume":"21","author":"WA Papenfuss","year":"2014","unstructured":"Papenfuss WA, Kukar M, Oxenberg J, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol. 2014;21:3008\u201314.","journal-title":"Ann Surg Oncol"},{"key":"1218_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ejso.2018.02.004","volume":"44","author":"YHM Claassen","year":"2018","unstructured":"Claassen YHM, Hartgrink HH, Dikken JL, et al. Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial. Eur J Surg Oncol. 2018;44:613\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"1218_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s10120-018-0795-0","volume":"22","author":"Y Kodera","year":"2019","unstructured":"Kodera Y, Yoshida K, Kumamaru H, et al. Introducing laparoscopic total gastrectomy for gastric cancer in general practice: a retrospective cohort study based on a nationwide registry database in Japan. Gastric Cancer. 2019;22:202\u201313.","journal-title":"Gastric Cancer"},{"key":"1218_CR31","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-012-2720-9","volume":"20","author":"M Tokunaga","year":"2013","unstructured":"Tokunaga M, Tanizawa Y, Bando E, et al. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013;20:1575\u201383.","journal-title":"Ann Surg Oncol"},{"key":"1218_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s10120-018-0883-1","volume":"22","author":"M Iwatsuki","year":"2019","unstructured":"Iwatsuki M, Yamamoto H, Miyata H, et al. Effect of hospital and surgeon volume on postoperative outcomes after distal gastrectomy for gastric cancer based on data from 145,523 Japanese patients collected from a nationwide web-based data entry system. Gastric Cancer. 2019;22:190\u2013201.","journal-title":"Gastric Cancer"},{"key":"1218_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01127-8","author":"M Iwatsuki","year":"2020","unstructured":"Iwatsuki M, Yamamoto H, Miyata H, et al. Association of surgeon and hospital volume with postoperative mortality after total gastrectomy for gastric cancer: data from 71,307 Japanese patients collected from a nationwide web-based data entry system. Gastric Cancer. 2020. https:\/\/doi.org\/10.1007\/s10120-020-01127-8.","journal-title":"Gastric Cancer"},{"key":"1218_CR34","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09507-1","author":"A Bausys","year":"2021","unstructured":"Bausys A, Umarik T, Luksta M, et al. Impact of the interval between neoadjuvant chemotherapy and gastrectomy on short- and long-term outcomes for patients with advanced gastric cancer. Ann Surg Oncol. 2021. https:\/\/doi.org\/10.1245\/s10434-020-09507-1.","journal-title":"Ann Surg Oncol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-021-01218-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-021-01218-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-021-01218-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:02:43Z","timestamp":1660176163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-021-01218-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s10120-021-01218-0","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by funding from Yakult Honsha Co., Ltd. S. H. Satake received research funding from Ono Pharmaceutical Co. Ltd., Daiichi Sankyo, Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Sanofi and honoraria from Bayer Co., Ltd., Bristol-Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan Co., Ltd., Merck Bio Pharma Co., Ltd., MSD Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Co., Ltd., and Yakult Honsha Co., Ltd. E. Oki received honoraria for lectures from Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Johnson & Johnson K.K., Merck Serono Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Yakult Honsha Co., Ltd. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights statement and informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}